Former Sen. Ben Sasse, R-Nebraska, had been given a prognosis of three to four months after announcing a pancreatic cancer diagnosis in December. By late April, Sasse described a different reality.
“Sasse said doctors initially gave him a prognosis of three to four months but said he has more time thanks to providence, prayer, and a miracle drug.” Ben Sasse, Former U.S. Senator
The miracle drug
Sasse referenced is daraxonrasib. On May 1, the Food and Drug Administration announced it would grant some patients early access to the experimental treatment developed by Redwood City-based Revolution Medicines. The move follows the release of clinical trial data in April that suggested the daily oral medication could significantly extend life for those with pancreatic cancer that has spread to other parts of the body.
The mechanics of expanded access
The FDA’s decision to allow an expanded access treatment protocol
provides a regulatory mechanism for patients to receive an investigational drug before it is fully approved. This mechanism is designed for patients with serious or life-threatening conditions who have exhausted standard treatment options and cannot enroll in a formal trial.
The timeline for this specific authorization moved quickly. USA Today reported that the FDA received the request from Revolution Medicines on April 28 and granted approval on April 30. Despite this speed, the process follows strict regulatory guidelines. Under FDA regulations, patients and caregivers are prohibited from applying directly to the pharmaceutical company. Access must be requested by a licensed treating physician.
Revolution Medicines stated it is working to implement the program in the U.S. as quickly as possible, emphasizing the need to ensure the process remains safe and equitable. Because the drug is not yet approved, it is being provided under these specific regulatory conditions to patients who are facing a terminal prognosis and have no other viable options.
Survival data and the clinical reality
The urgency surrounding daraxonrasib is driven by the stark mortality rates associated with metastatic pancreatic ductal adenocarcinoma (PDAC). According to the National Cancer Institute, pancreatic cancer is among the deadliest forms of the disease, accounting for 8% of all cancer deaths. In 2026, estimates indicate more than 52,000 people will die from the disease.
For patients whose cancer has already spread to distant parts of the body, the NCI reports that only about 3% survive five years after diagnosis. In this context, the trial results released by Revolution Medicines on April 13 provide new clinical data regarding patient outcomes. The data showed that patients taking daraxonrasib lived a median of 13.2 months—nearly double the 6.7-month median survival seen in patients receiving standard chemotherapy.
While the doubling of survival time is a significant data point, the company continues to monitor the results as part of the ongoing development process. The company has sought approval for the drug through the FDA’s priority review program and has received a priority review voucher to accelerate the development of the treatment for this unmet medical need.
The role of advocacy and future hurdles
Patient advocacy groups have reacted to the trial results with a mixture of optimism and caution. Anna Berkenblit, chief scientific and medical officer with the Pancreatic Cancer Action Network, described the results as truly remarkable
in a statement.
“While these results represent a huge step forward in the field, they are just the beginning,” Berkenblit said. “We know that resistance to treatment can develop, and research into drug combinations is needed to overcome these challenges.” Anna Berkenblit, Pancreatic Cancer Action Network
Berkenblit noted that while the current results are a positive development, more study is needed to continue progress against the deadly disease
. This underscores the ongoing need for continued research and the development of comprehensive treatment plans for patients with advanced pancreatic cancer.
The biological mechanism of daraxonrasib is not detailed extensively in current reporting, but its application is not limited to pancreatic cancer. According to Yahoo, the pill is also being evaluated in other late-stage trials, including for non-small cell lung cancer. This suggests that the drug’s target may be applicable to other malignancies, potentially expanding the scope of the expanded access program if further trials prove successful.
For now, the drug remains a lifeline for a specific subset of patients—those who have been previously treated for pancreatic cancer and have a physician willing to navigate the FDA’s expanded access requirements. The transition from a miracle drug
for a few to a standard of care for many depends on the outcome of the ongoing priority review and the ability of researchers to combat the inevitable development of drug resistance.
